Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB4330 in Advanced Solid Tumors
NCT05707676Phase 1Terminated
- Sponsor
- L&L Biopharma Co., Ltd.
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of LB4330 in solid tumor, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 3 more (2 arms), sponsored by L&L Biopharma Co., Ltd. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 24 months, Dose Limiting Toxicities at 21 days and 1 more. Started Nov 2022; status: terminated.
02
Drugs
LB4330
03
Conditions
solid tumorgastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic ductal adenocarcinoma (PDAC)ovarian cancer
Beyond the preview
Go deeper on NCT05707676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05707676.